Posted from: Thursday, May 05, 2016 - 12:08 PM - Present

FDA Approved Cabometyx

April 25, 2016 – The FDA approved Cabometyx (cabozantinib), manufactured by Exelixis, for the treatment of patients with advanced renal cell carcinoma (RCC). Cabometyx is for patients who have received prior anti-angiogenic therapy. This treatment interferes with several receptor tyrosine kinases, which are proteins that promote the growth and spread of tumors. Cabometyx is available in 20mg, 40mg, and 60mg tablets, and the recommended dose is 60mg once daily. In clinical trials, survival for RCC patients taking Cabometyx was about five months longer than RCC patients taking the comparator drug, Afinitor® (everolimus – Novartis). The progression-free survival rate was about twice as long (7.4 months vs. 3.8 months), and the objective response rate, a measure of tumor size decrease, was 21% for Cabometyx and 5% for Afinitor.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Monday, May 29, 2017 - 10:44 AM.